Latest Breaking News On - Bpifrance entreprise - Page 1 : vimarsana.com

Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris Offer oversubscribed 4 times, with global demand totaling €28.1 million Capital increase of approximately €8 million, after full exercise of the Extension Clause Trading in the Company s shares begins on February 5, 2021 (FR0011651694 ALPHE) Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on the Euronext Growth market in Paris. Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says: I am particularly sensitive to the high level of interest the financial community has shown in our IPO project, both institutional and individual investors. I would like to thank all our shareholders, longstanding and new, who have chosen to accompany us

United statesFrance generalUnited kingdomPherecydes pharmaPhilippe rousseauBpifrance entrepriseKostenloser wertpapierhandelNicolas merigeauDusan oresanskyEntreprise innovanteRegulations of the french market authority autoritEuropean parliamentEarly access programFinancial servicesCompany supervisory boardProspectus directive of the european union